Search Results

You are looking at 51 - 60 of 295 items for :

  • "Neoadjuvant chemotherapy" x
  • Refine by Access: All x
Clear All
Full access

CLO23-040: Electrocardiographic Findings in Cancer Patients Receiving Chemotherapy From the Colombian Coffee Triangle Region

Andres Garcia, David Medina, Alejandra Palacio, Andrés Vallejo, Luz Adriana Díaz, Juan Darío Franco, Tatiana Taborda, and María José Rojas

Background: Some antineoplastic agents are known for their cardiotoxicity, especially anthracyclines, used for breast cancer neoadjuvant chemotherapy and induction treatment for some hematological malignancies. Nevertheless, there is scarce

Full access

Trends in Neoadjuvant Approaches in Pancreatic Cancer

Lingling Du and Andrea Wang-Gillam

a better insight into the role and best strategy of neoadjuvant chemoRT. Neoadjuvant Chemotherapy PDAC has a high propensity for early development of metastasis. The role of RT in PDAC remains controversial even in the adjuvant setting and

Full access

Wilms Tumor (Nephroblastoma), Version 2.2021, NCCN Clinical Practice Guidelines in Oncology

Frank Balis, Daniel M. Green, Clarke Anderson, Shelly Cook, Jasreman Dhillon, Kenneth Gow, Susan Hiniker, Rama Jasty-Rao, Chi Lin, Harold Lovvorn III, Iain MacEwan, Julian Martinez-Agosto, Elizabeth Mullen, Erin S. Murphy, Mark Ranalli, Daniel Rhee, Denise Rokitka, Elisabeth (Lisa) Tracy, Tamara Vern-Gross, Michael F. Walsh, Amy Walz, Jonathan Wickiser, Matthew Zapala, Ryan A. Berardi, and Miranda Hughes

neoadjuvant chemotherapy is determined at week 6, especially if a biopsy was not performed at initial presentation. Information that can be obtained through biopsy is limited. A diagnosis of FHWT obtained on a biopsy implies that focal or diffuse anaplasia

Full access

Induction Chemotherapy for Head and Neck Cancer: Will History Repeat Itself?

Athanassios Argiris

Surg 1987 ; 10 : 19 – 30 . 3 Taylor SGT . Why has so much chemotherapy done so little in head and neck cancer? J Clin Oncol 1987 ; 5 : 1 – 3 . 4 Rosenthal DI Pistenmaa DA Glatstein E . A review of neoadjuvant chemotherapy

Full access

Adjuvant Therapy for Soft Tissue Sarcoma

Scott M. Schuetze and Michael E. Ray

. Ifosfamide in the adjuvant therapy of soft tissue sarcomas . Oncology 2003 ; 65 ( suppl 2 ): 80 – 84 . 30 DeLaney TF Spiro IJ Suit HD . Neoadjuvant chemotherapy and radiotherapy for large extremity soft-tissue sarcomas . Int J Radiat Oncol

Full access

NCCN Guidelines Update: Evolving Radiation Therapy Recommendations for Breast Cancer

Kilian E. Salerno

invasive carcinoma. These recommendations are not applicable for APBI or patients who have received neoadjuvant chemotherapy. Hypofractionation: Preferred for Whole-Breast RT For most women receiving whole-breast irradiation, hypofractionation is

Full access

Importance of Node Dissection in Relation to Neoadjuvant and Adjuvant Therapy

William C. Huang and Bernard H. Bochner

, multinational, multicenter, phase III study . J Clin Oncol 2000 ; 18 : 3068 – 3077 . 19. Grossman HB Natale RB Tangen CM . Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer . N Engl J Med

Full access

Locoregional Management of Early-Stage Breast Cancer

Presented by: Benjamin O. Anderson and Janice A. Lyons

neoadjuvant treatment,” he said. The 4-arm SENTINA trial concluded that SLNB is reliable before neoadjuvant chemotherapy is given. 12 But after neoadjuvant chemotherapy and with conversion from clinically positive to clinically negative, SLNB has a high false

Full access

CLO20-055: Optimal Timing of Radical Surgery From Diagnosis in Muscle Invasive Bladder Cancer (MIBC)

Saurabh Parasramka, Quan Chen, Bin Huang, Peng Wang, and Zin Myint

after diagnosis adversely effects survival outcomes. Neoadjuvant chemotherapy (NAC) has become the standard of care for appropriate patients, which delays definitive surgery. Optimal timing of surgery from the time of diagnosis is uncertain when done

Full access

CLO24-092: Neoadjuvant Tyrosine Kinase Inhibitors (TKIs) Efficacy in EGFR Positive Stage III Non–Small Cell Lung Cancer (NSCLC): A Systematic Review and Meta-Analysis

John Kelvin Lalusis and John Lois Padayao

Background: Current treatment guidelines for potentially resectable stage IIIA NSCLC primarily include neoadjuvant chemotherapy with the goal of pathological downstaging and complete surgical resection. With favorable anti-tumor activity and